Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance

Blood. 2018 Aug 9;132(6):666-670. doi: 10.1182/blood-2018-02-833608. Epub 2018 Jun 18.

Authors

Christina Kalpadakis¹, Gerassimos A Pangalis², Sotirios Sachanas², Pantelis Tsirkinidis², Flora N Kontopidou³, Maria Moschogiannis², Xanthi Yiakoumis², Efstathios Koulieris², Maria N Dimopoulou⁴, Stella I Kokkoris⁴, Marie-Christine Kyrtsonis⁵, Marina P Siakantaris⁶, Gerassimos Tsourouflis⁷, Penelope Korkolopoulou⁸, Dimitra Rontogianni⁹, Panagiotis Tsaftaridis⁴, Eleni Plata⁴, Helen A Papadaki¹, Panagiotis Panagiotidis⁵, Maria K Angelopoulou⁴, Theodoros P Vassilakopoulos⁴

Affiliations

¹ Department of Hematology, University Hospital, University of Crete, Heraklion, Crete, Greece.
² Department of Hematology, Athens Medical Center-Psychiko Branch, Athens, Greece.
³ Second Department of Internal Medicine, National and Kapodistrian University of Athens, Hippocrateio General Hospital, Athens, Greece.
⁴ Department of Haematology.
⁵ First Propedeutic Department of Internal Medicine.
⁶ First Department of Internal Medicine, and.
⁷ Second Department of Surgery, Propedeutic, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
⁸ Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece; and.
⁹ Department of Pathology, Evangelismos General Hospital, Athens, Greece.

PMID: 29914978
DOI: 10.1182/blood-2018-02-833608

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / therapeutic use*
Drug Administration Schedule
Drug Evaluation
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Maintenance Chemotherapy
Male
Middle Aged
Progression-Free Survival
Remission Induction
Retrospective Studies
Rituximab / therapeutic use*
Splenic Neoplasms / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Rituximab